KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Equity Average (2019 - 2025)

Historic Equity Average for Castle Biosciences (CSTL) over the last 7 years, with Q3 2025 value amounting to $461.2 million.

  • Castle Biosciences' Equity Average rose 664.48% to $461.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $461.2 million, marking a year-over-year increase of 664.48%. This contributed to the annual value of $423.6 million for FY2024, which is 717.15% up from last year.
  • Per Castle Biosciences' latest filing, its Equity Average stood at $461.2 million for Q3 2025, which was up 664.48% from $447.8 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Equity Average peaked at $461.2 million during Q3 2025, and registered a low of $382.0 million during Q2 2023.
  • Its 5-year average for Equity Average is $415.2 million, with a median of $413.2 million in 2024.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 38211.06% in 2021, then tumbled by 822.74% in 2023.
  • Quarter analysis of 5 years shows Castle Biosciences' Equity Average stood at $411.7 million in 2021, then fell by 1.56% to $405.3 million in 2022, then fell by 4.14% to $388.5 million in 2023, then increased by 15.42% to $448.4 million in 2024, then increased by 2.85% to $461.2 million in 2025.
  • Its Equity Average was $461.2 million in Q3 2025, compared to $447.8 million in Q2 2025 and $448.1 million in Q1 2025.